Holen Sie sich die Stockscreener-App
0.9963
5.11%
-0.0537
Handel nachbörslich:
1.01
0.0137
+1.38%
Schlusskurs vom Vortag:
$1.05
Offen:
$1.07
24-Stunden-Volumen:
1.28M
Relative Volume:
0.80
Marktkapitalisierung:
$126.72M
Einnahmen:
$79.18M
Nettoeinkommen (Verlust:
$-136.99M
KGV:
-0.9446
EPS:
-1.0547
Netto-Cashflow:
$-120.11M
1W Leistung:
-9.43%
1M Leistung:
-69.34%
6M Leistung:
-74.90%
1J Leistung:
-70.52%
1-Tages-Spanne:
$0.9811
$1.09
1-Wochen-Bereich:
$0.9811
$1.22
52-Wochen-Spanne:
$0.7796
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Branche
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
0.9963 | 133.55M | 79.18M | -136.99M | -120.11M | -1.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Eingeleitet | Guggenheim | Buy |
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-06-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Investors to Learn More About the Investigation | NYSE:ADCT | Press Release - Stockhouse
Are medical stocks lagging ADC Therapeutics (ADCT) this year? - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Stockholders to Reach Out - ACCESS Newswire
ADC Therapeutics SA (ADCT) reports Q1 loss, beats revenue estimates - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Stockholders to Connect - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
ADC Therapeutics falls on confirmatory trial data for lymphoma therapy - MSN
ADCT Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCLSlideshow - Seeking Alpha
ADC Therapeutics Shares Fall After HC Wainwright Downgrade - marketscreener.com
This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday - Benzinga
ADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA DataHas The Bull Case Changed? - Yahoo Finance
ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursda - Benzinga
ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In Strategy (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics SA (ADCT) Stock Price, Quote, News & History - Benzinga
Why Is ADC Therapeutics Stock Falling On Friday?ADC Therapeutics (NYSE:ADCT) - Benzinga
Why Is ADC Therapeutics Stock Falling Thursday? - Sahm
ADC Therapeutics’ Zynlonta Clears Phase III PFS Bar But Safety Concerns Cloud FDA Path - Citeline News & Insights
ADCT stock plunges on safety concerns despite positive lymphoma data - MSN
ADCT Downgraded by RBC Capital -- Price Target Lowered to $2.00 - GuruFocus
Zynlonta Lotis position in DLBCL strains ADC shares - BioWorld News
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data - Yahoo Finance
ADC Therapeutics plunges after patient deaths in blood cancer drug trial - Reuters
ADC Thera falls on trial data for lymphoma drug (ADCT:NYSE) - Seeking Alpha
RBC Downgrades ADC Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Keeps Speculative Risk - marketscreener.com
An ADC specialist sinks on safety concerns for blood cancer drug - Yahoo Finance
RBC Capital cuts ADC Therapeutics stock rating on trial results By Investing.com - Investing.com UK
ADC Therapeutics stock plunges on trial safety concerns By Investing.com - Investing.com Australia
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirma - GuruFocus
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma - BioSpace
Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise - Kavout
ADC Therapeutics stock plunges on trial safety concerns - Investing.com
ADC Therapeutics reports positive phase 3 trial results By Investing.com - Investing.com India
ADC Therapeutics reports positive phase 3 trial results - Investing.com
ADCT: LOTIS-5 met its PFS endpoint, with durable CRs but higher Grade 5 events in elderly patients - TradingView
ADCT: LOTIS-5 met its primary PFS endpoint, with Lonca-R showing higher CR rates than R-GemOx - TradingView
ADC Therapeutics' Drug Regimen to Treat B-Cell Lymphoma Meets Primary Endpoint of Progression-Free Survival in Phase 3 Trial - marketscreener.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ADC Therapeutics (NYSE: ADCT) director gets 45K RSUs, 12.6K shares withheld - Stock Titan
ADC Therapeutics (ADCT) director receives RSU award and shares withheld for taxes - Stock Titan
ADC Therapeutics (ADCT) director logs RSU grant and tax withholding on Form 4 - Stock Titan
ADC Therapeutics (ADCT) director granted 45K RSUs, 2.6K shares withheld - Stock Titan
ADC Therapeutics (ADCT) director receives 45,000 RSUs and 2,156-share tax withholding - Stock Titan
ADC Therapeutics (ADCT) director RSU grant and 12,600-share tax withholding - Stock Titan
ADC Therapeutics (NYSE: ADCT) director gets RSU grant and tax withholding - Stock Titan
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):